Frequency of IL-10+CD19+ B cells in patients with prostate cancer compared to patients with benign prostatic hyperplasia

Nazmabadi Roya,Taheri Fatemeh,Mohammad-Alibeigi Faramarz,Sabzevary-Ghahfarokhi Milad,Sanaei Mohammad-Javad,Salehi-Vanani Najmeh,Mirzaei Yousef,Bagheri Nader
DOI: https://doi.org/10.4314/ahs.v20i3.31
2020-10-07
African Health Sciences
Abstract:Background: The function of the immune system in prostate cancer (PC) might promote carcinogenesis. PC is a common cancer in men. Regulatory B cells (Bregs) are a new subtype of B cells that have suppressive roles in the immune system. Inter- leukin-10 (IL-10) is a dominant mediator of immune suppression released by Bregs. Objective: The purpose of this research was to examine the frequency of CD19+IL10+ B cells and IL-10 mRNA expression in patients with PC compared to patients with benign prostatic hyperplasia (BPH). Methods: Forty paraffin tissue samples from patients with PC and 32 paraffin tissue samples from patients with BPH were en- tered in this study. The immunohistochemistry staining was used to evaluate the pattern expression of CD19 and IL-10 markers. IL-10 mRNA expression in fresh tissue was determined by real time-polymerase chain reaction (RT-PCR). Results: The frequency of CD19+IL-10+ B cells and IL-10 mRNA expression in PC patients were significantly higher than patients with BPH. Also, there was no meaningful relationship between the frequency of IL-10+CD19+ B cells and gleason scores in patients with PC. Conclusions: Our findings suggested that frequency of IL-10+CD19+ B cells correlates with progressive stage of PC. Keywords: Prostate cancer; benign prostatic hyperplasia; IL-10+CD19+ B cells.
medicine, general & internal
What problem does this paper attempt to address?